Advertisement

Pharmaceutisch Weekblad

, Volume 11, Issue 4, pp 121–123 | Cite as

Two different dosages of ciprofloxacin in patients with respiratory tract infections

  • T. Brutel de la Rivière
  • M. S. M. Daniëls-Bosman
  • G. P. M. ten Velde
Therapeutic Interventions in Lower Respiratory Tract Infections
  • 23 Downloads

Abstract

Fifty-one patients with chronic obstructive lung disease with a proven bacterial respiratory tract infection were treated with ciprofloxacin 500 mg twice daily or 750 mg twice daily. Both dosages were given orally for approximately 10 days. The higher dosage showed a reduced amount of reinfections and relapses (19% and 16% versus 5% and 0%). The overall results were the same in both groups. Adverse reactions were mild: nausea and visual disturbances were seen in five patients. Eights patients had slight liver test abnormalities. In one patient a seizure occurred. All adverse reactions were of a temporary nature.

Keywords

Ciprofloxacin Pulmonary diseases, chronic obstructive Respiratory tract infections 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ingram RH Jr. Chronic bronchitis, emphysema, and airways obstruction. In: Petersdorf RO, Adams RO, Braunwals E, Isselbacher KJ, Martin JB, Wilson JD, eds. Harrison's principles of internal medicine. 10th ed. New York: McGraw-Hill Book Co., 1983:1550.Google Scholar
  2. 2.
    Rose RM, Pinkston P, O'Donnell C, Jensen A. Viral infection of the lower respiratory tract. Clin Chest Med 1987;8:411.Google Scholar
  3. 3.
    Empey DW, Laitinen LA, Jacobs L, Gold WM, Nadel JA. Mechanism of bronchial hyperreactivity in normal subjects after upper respiratory tract infection. Am Rev Respir Dis 1976;113:131–9.PubMedGoogle Scholar
  4. 4.
    Smith CB, Kanner RE, Golden CA, Klauber MR, Renzetti AD Jr. Effect of viral infection on pulmonary diseases. J Infect Dis 1980;141:271–80.PubMedGoogle Scholar
  5. 5.
    Chodosh S. Acute bacterial exacerbations in bronchitis and asthma. Am J Med 1987;82:156–63.PubMedGoogle Scholar
  6. 6.
    Davies BI, Maesen FPV. Quinolones in chest infections. J Antimicrob Chemother 1986;18:296–9.PubMedGoogle Scholar
  7. 7.
    Haverkorn MJ. Ciprofloxacin therapy of respiratory tract infection withPseudomonas aeruginosa. Eur J Clin Microb 1988;7:661–4.Google Scholar
  8. 8.
    Hoogkamp-Korstanje JAA, Klein SJ. Treatment of acute exacerbations of chronic bronchitis with ciprofloxacin. Pharm Weekbl [Sci] 1987;9(Suppl):60–3.Google Scholar
  9. 9.
    Wijnands WJA, Vree TB, Baars AM, Van Herwaarden CLA. The influence of the 4-quinolones ciprofloxacin, pefloxacin and ofloxacin on the elimination of theophyl-line. Pharm Weekbl [Sci] 1987;9(Suppl):72–5.Google Scholar
  10. 10.
    Raoof S, Wollschlager CM, Khan FA. Ciprofloxacin increases serum theophylline levels. Chest 1985;88:32.Google Scholar
  11. 11.
    Davies BI, Maesen FPV, Baur C. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. Eur J Clin Microb 1986;5:226–31.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1989

Authors and Affiliations

  • T. Brutel de la Rivière
    • 1
  • M. S. M. Daniëls-Bosman
    • 2
  • G. P. M. ten Velde
    • 1
  1. 1.Department of PulmonologyUniversity Hospital MaastrichtBX Maastrichtthe Netherlands
  2. 2.Department of Clinical MicrobiologyUniversity Hospital Maastrichtthe Netherlands

Personalised recommendations